BibTex format
@article{Udeh-Momoh:2021:10.1136/bmjopen-2020-043114,
author = {Udeh-Momoh, CT and Watermeyer, T and Price, G and de, Jager Loots CA and Reglinska-Matveyev, N and Ropacki, M and Ketter, N and Fogle, M and Raghavan, N and Arrighi, M and Brashear, R and Di, J and Baker, S and Giannakopoulou, P and Robb, C and Bassil, D and Cohn, M and McLellan-Young, H and Crispin, J and Lakey, K and Lisa, C and Chowdary, Seemulamoodi Y and Kafetsouli, D and Perera, D and Car, J and Majeed, A and Ward, H and Ritchie, K and Perneczky, R and Kivipelto, M and Scott, D and Bracoud, L and Saad, Z and Novak, G and Ritchie, CW and Middleton, L},
doi = {10.1136/bmjopen-2020-043114},
journal = {BMJ Open},
pages = {1--12},
title = {Protocol of the cognitive health in ageing register: investigational, observational and trial studies in dementia research (CHARIOT): prospective readiness cOhort (PRO) SubStudy.},
url = {http://dx.doi.org/10.1136/bmjopen-2020-043114},
volume = {11},
year = {2021}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - INTRODUCTION: The Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy (CPSS), sponsored by Janssen Pharmaceutical Research & Development LLC, is an Alzheimer's disease (AD) biomarker enriched observational study that began 3 July 2015 CPSS aims to identify and validate determinants of AD, alongside cognitive, functional and biological changes in older adults with or without detectable evidence of AD pathology at baseline. METHODS AND ANALYSIS: CPSS is a dual-site longitudinal cohort (3.5 years) assessed quarterly. Cognitively normal participants (60-85 years) were recruited across Greater London and Edinburgh. Participants are classified as high, medium (amnestic or non-amnestic) or low risk for developing mild cognitive impairment-Alzheimer's disease based on their Repeatable Battery for the Assessment of Neuropsychological Status performance at screening. Additional AD-related assessments include: a novel cognitive composite, the Global Preclinical Alzheimer's Cognitive Composite, brain MRI and positron emission tomography and cerebrospinal fluid analysis. Lifestyle, other cognitive and functional data, as well as biosamples (blood, urine, and saliva) are collected. Primarily, study analyses will evaluate longitudinal change in cognitive and functional outcomes. Annual interim analyses for descriptive data occur throughout the course of the study, although inferential statistics are conducted as required. ETHICS AND DISSEMINATION: CPSS received ethical approvals from the London-Central Research Ethics Committee (15/LO/0711) and the Administration of Radioactive Substances Advisory Committee (RPC 630/3764/33110) The study is at the forefront of global AD prevention efforts, with frequent and robust sampling of the well-characterised cohort, allowing for detection of incipient pathophysiological, cognitive and functional changes that could inform therape
AU - Udeh-Momoh,CT
AU - Watermeyer,T
AU - Price,G
AU - de,Jager Loots CA
AU - Reglinska-Matveyev,N
AU - Ropacki,M
AU - Ketter,N
AU - Fogle,M
AU - Raghavan,N
AU - Arrighi,M
AU - Brashear,R
AU - Di,J
AU - Baker,S
AU - Giannakopoulou,P
AU - Robb,C
AU - Bassil,D
AU - Cohn,M
AU - McLellan-Young,H
AU - Crispin,J
AU - Lakey,K
AU - Lisa,C
AU - Chowdary,Seemulamoodi Y
AU - Kafetsouli,D
AU - Perera,D
AU - Car,J
AU - Majeed,A
AU - Ward,H
AU - Ritchie,K
AU - Perneczky,R
AU - Kivipelto,M
AU - Scott,D
AU - Bracoud,L
AU - Saad,Z
AU - Novak,G
AU - Ritchie,CW
AU - Middleton,L
DO - 10.1136/bmjopen-2020-043114
EP - 12
PY - 2021///
SN - 2044-6055
SP - 1
TI - Protocol of the cognitive health in ageing register: investigational, observational and trial studies in dementia research (CHARIOT): prospective readiness cOhort (PRO) SubStudy.
T2 - BMJ Open
UR - http://dx.doi.org/10.1136/bmjopen-2020-043114
UR - https://www.ncbi.nlm.nih.gov/pubmed/34168021
UR - https://bmjopen.bmj.com/content/11/6/e043114
UR - http://hdl.handle.net/10044/1/91510
VL - 11
ER -
